natgillin/translations-raw huggingface dataset:
An agent for treating or preventing mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia, comprising the azole derivative or pharmaceutically acceptable salt thereof according to any one of Claims 1 to 9 as an active ingredient. 
Sredstvo za uporabu za tretman ili sprječavanje poremećaja raspoloženja, anksioznosti, shizofrenije, Alzheimerove bolesti, Parkinsonove bolesti, Huntingtonove koree, poremećaja u prehrani, hipertenzije, gastrointestinalne bolesti, ovisnosti o drogama, epilepsije, cerebralnog infarkta, cerebralne ishemije, cerebralnog edema, ozljede glave, upale, imunološki povezanih bolesti, ili alopecije, naznačeno time da kao aktivni sastojak sadrži derivat azola ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1 do 10.
A surgical instrumental kit for an operations on the human spinal column comprising: 
Set kiruškog instrumenta za operacije na ljudskoj kralješnici, koji sadrži:
A surgical instrumental kit according to claim 1, wherein said substantially flat portion (4) comprises a pair of curved portions (3a, 3b) shaped to blend with the body (2). 
Set kiruškog instrumenta prema zahtjevu 1, gdje u biti plosnati dio (4) obuhvaća par zaobljenih dijelova (3a, 3b) oblikovanih tako da se stope s tijelom (2).
A surgical instrumental kit according to claim 1, wherein said handle body (2) is a plate-like element with a substantially curved configuration. 
Set kiruškog instrumenta prema zahtjevu 1, gdje je tijelo drške (2) pločasti element s u biti zaobljenom konfiguracijom.
A surgical instrumental kit according to one or more of preceding claims, wherein said substantially flat portion (4) has a plurality of teeth (6). 
Set kiruškog instrumenta prema jednom ili više prethodnih zahtjeva, gdje taj u biti plosnati dio (4) ima više zubaca (6).
is selected from the group consisting of: and Ya is CH2. 
[image] odabrana je iz skupine koju čine: [image] i Ya je CH2.
The compound for use according to claim 7, wherein diabetes is type I diabetes. 
Spoj za uporabu prema zahtjevu 7, naznačen time, da dijabetes je dijabetes tipa I.
The compound for use according to claim 7, wherein diabetes is type II diabetes. 
Spoj za uporabu prema zahtjevu 7, naznačen time, da dijabetes je dijabetes tipa II.
A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (V) according to any of claims 1 to 4 in combination with a therapeutically effective amount of insulin, insulin derivative or mimetic; insulin secretagogue; insulinotropic sulfonylurea receptor ligand; PPAR ligand; insulin sensitizer; biguanide; alpha-glucosidase inhibitors; GLP-1, GLP-1 analog or mimetic; DPPIV inhibitor; HMG-CoA reductase inhibitor; squalene synthase inhibitor; FXR or LXR ligand; cholestyramine; fibrates; nicotinic acid; or aspirin. 
Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu spoja formule (V) prema bilo kojem od zahtjeva 1 do 4, u kombinaciji s terapeutski učinkovitom količinom inzulina, derivata inzulina ili mimetika inzulina; sekretagoga inzulina; inzulinotropnog liganda receptora sulfoniluree; liganda PPAR; inzulinskog senzibilizatora; bigvanida; inhibitora alfaglukozidaze; GLP-1, GLP-l-analoga ili GLP-1 -mimetika; inhibitora DPPIV; inhibitora reduktaze HMG-CoA; inhibitora sinteze skvalena; liganda FXR ili liganda LXR; kolestiramina; fibrata; nikotinske kiseline; ili aspirina.
A product comprising a compound of formula (V) according to any of claims 1 to 4 and an agent selected from the group consisting of insulin, insulin derivative or mimetic; insulin secretagogue; insulinotropic sulfonylurea receptor ligand; PPAR ligand; insulin sensitizer; biguanide; alpha-glucosidase inhibitors; GLP-1, GLP-1 analog or mimetic; DPPIV inhibitor; HMG-CoA reductase inhibitor; squalene synthase inhibitor; FXR or LXR ligand; cholestyramine; fibrates; nicotinic acid, and aspirin for simultaneous, separate or sequential use in therapy. 
Proizvod, naznačen time, da obuhvaća spoj formule (V) prema bilo kojem od zahtjeva 1 do 4, i jedno sredstvo odabrano iz skupine koju čine inzulin, derivat inzulina ili mimetik inzulina; sekretagog inzulina; inzulinotropni ligand receptora sulfoniluree; ligand PPAR; inzulinski senzibilizator; bigvanid; inhibitori alfaglukozidaze; GLP1, GLP-l-analog ili GLP-1 -mimetik; inhibitor DPPIV: inhibitor reduktaze HMG-CoA; inhibitor sinteze skvalena; ligand FXR ili ligand LXR; kolestiramin; fibrati; nikotinska kiselina; i aspirin, za istovremenu, odvojenu ili uzastopnu uporabu u liječenju.
A packaging material (11) for a pharmaceutical product, said packaging material (11) having a coloured element (12) which, at a predetermined temperature below which the pharmaceutical product must be kept, discolours partially, revealing a marking (12'), wherein: 
Pakirni materijal (11) za farmaceutski proizvod, gdje taj pakirni materijal (11) ima obojani element (12) koji na predodređenoj temperaturi ispod koje se farmaceutski proizvod treba čuvati, djelomično izgubi boju, te time otkrije oznaku (12'), pri čemu:
said element (12) is formed by a first portion, which forms said marking (12') printed with a conventional ink, and by a second portion (12") printed with a thermochromic ink; 
navedeni element (12) je ostvaren s prvim dijelom koji oblikuje navedenu oznaku (12') otisnutu konvencionalnom tiskarskom bojom, i s drugim dijelom (12'') koji je otisnut termokromnom tiskarskom bojom;
said first portion (12') and second portion (12") are arranged so that said first portion (12') is substantially invisible below said predetermined temperature, but becomes visible when said predetermined temperature is reached or exceeded; characterised in that 
navedeni prvi dio (12') i drugi dio (12'') su raspoređeni tako, da je navedeni prvi dio (12') uglavnom nevidljiv ispod spomenute predodređene temperature, ali postaje vidljiv kada se spomenuta predodređena temperatura dosegne ili premaši; naznačen time, da
The packaging material (11) according to Claim 1, in which the thermochromic ink is of the reversible type. 
Pakirni materijal (11) prema zahtjevu 1, naznačen time, da je termokromna tiskarska boja reverzibilne vrste.
The packaging material (11) according to any of Claims 1, 2, or 3, in which the colour of the thermochromic ink is, below said predetermined temperature, as similar as possible to that of the conventional ink. 
Pakirni materijal (11) prema bilo kojem od zahtjeva 1, 2 ili 3, naznačen time, da je obojenje termokromne tiskarske boje ispod spomenute predodređene temperature, što je više moguće slično onom obojenju od konvencionalne tiskarske boje.
obtaining a packaging material (11); 
dobavljanje pakirnog materijala (11);
printing said marking (12') thereon using an ink of the conventional type; applying a thermochromic ink, which is coloured below said predetermined temperature, but becomes colourless when said predetermined temperature is reached or exceeded, so that said marking (12") is substantially invisible below said predetermined temperature, but becomes visible when said predetermined temperature is reached or exceeded, characterised in that said thermochromic ink is applied so as to form a layer (12") which is situated alongside said marking (12'). 
nanošenje termokromne tiskarske boje koja ima obojenje ispod spomenute predodređene temperature, ali postaje bezbojna kada se dosegne ili premaši spomenuta predodređena temperatura, tako da navedena oznaka (12') postaje uglavnom nevidljiva ispod spomenute predodređene temperature, no opet postaje vidljiva kada se dosegne ili premaši spomenuta predodređena temperatura, naznačen time, da se navedena termokromna tiskarska boja nanosi tako, da stvara sloj (12'') koji je smješten granično pored navedene oznake (12').
The method according to any of Claims 6, 7, or 8, in which the colour of the thermochromic ink is, below said predetermined temperature, as similar as possible to that of the conventional ink with which the marking (12') has been printed. 
Postupak prema bilo kojem od zahtjeva 6, 7 ili 8, naznačen time, da je obojenje termokromne tiskarske boje ispod spomenute predodređene temperature, što je više moguće slično onom obojenju od konvencionalne tiskarske boje kojom je otisnuta oznaka (12').
may be an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms, Y may be hydrogen, -OH, -N(R11)(R12), -N(R11)O(R12), in which 
može biti alkil-skupina koja ima od 1 do 5 atoma ugljika, opcijski supstituirana s jednom ili više alkil-skupina koje imaju od 1 do 5 atoma ugljika, Y može biti vodik, -OH, -N(R11)(R12), -N(R11)0(R12), gdje
may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, or R11 together with R12 forms a 4- to 7-membered heterocycle, 
može biti vodik, alkil-skupina koja ima od 1 do 5 atoma ugljika, alkoksi- skupina koja ima od 1 do 3 atoma ugljika, ili R11 zajedno s R12 tvori 4-člani do 7-člani heterocikl,
may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, COR', COOR', CON(R')(R") with R' and R", which may be identical or different each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms, or R12 together with R11, forms a 4- to 7-membered heterocycle, 
može biti vodik, alkil-skupina koja ima od 1 do 5 atoma ugljika, alkoksi- skupina koja ima od 1 do 3 atoma ugljika, COR', COOR', CON(R')(R"), s R' i R" koji mogu biti međusobno isti ili različiti, a predstavljeni su vodikom i alkil-skupinom koja ima od 1 do 5 atoma ugljika, ili R12 zajedno s R11 tvori 4-člani do 7-člani heterocikl,
and R2, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, 
, i R2 koji mogu biti međusobno isti ili različiti, mogu biti vodik, alkil-skupina koja ima od 1 do 5 atoma ugljika,
Compound according to Claim 1, characterized in that residue A is chosen from the group comprising the group CH2, the group C(CH3)2, the group CH2OCH2CH2, and the group CH2OCH2CH2CH2. 
Spoj prema zahtjevu 1, naznačen time, da je ostatak A odabran iz skupine koju čine: skupina CH2, skupina C(CH3)2, skupina CH2OCH2CH2, i skupina CH2OCH2CH2CH2.
Compound according to Claim 1, characterized in that R11 and R12, which may be identical or different each other, are a hydrogen atom, an alkyl group having from 1 to 3 carbon atoms, or together form a 5- or 6-membered heterocycle. 
Spoj prema zahtjevu 1, naznačen time, da R11 i R12 koji mogu biti međusobno isti ili različiti, predstavljaju atom vodika, aikil-skupinu koja ima od 1 do 3 atoma ugljika, ili zajedno tvore 5-člani ili 6-člani heterocikl.
Compound according to Claim 1, characterized in that R3, R4 and R8, which may be identical or different each other, are chosen from the group comprising a hydrogen atom, an alkyl group having from 1 to 3 carbon atoms, an alkoxy group having 1 or 2 carbon atoms, a Br, Cl or F atom, an OH group, a nitro group, a trifluoromethyl group or a group N(R')(R"), -N(R')COR", -CN, - CONR'R", -SO2NR'R", -SO2R', with R' and R", which may be identical or different each other, represented by a hydrogen atom and an alkyl group having from 1 to 3 carbon atoms. 
Spoj prema zahtjevu 1, naznačen time, da R3, R4 i R8 koji mogu biti međusobno isti ili različiti, odabrani su iz skupine koju čine: atom vodika, alkil-skupina koja ima od 1 do 3 atoma ugljika, alkoksi-skupina koja ima 1 ili 2 atoma ugljika, atom Br, Cl ili F, OH-skupina, nitro-skupina, trifluorometil-skupina ili skupina N(R')(R"), -N(R')COR", -CN, -CONR'R", -SO2NR'R", -SO2NR' s R' i R" koji mogu biti međusobno isti ili različiti, a predstavljeni su vodikom i alkil-skupinom koja ima od 1 do 3 atoma ugljika.
Pharmaceutical composition according to Claim 9, characterized in that the said physiologically acceptable acids are chosen from the group comprising hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, ascorbic acid, benzoic acid, citric acid, fumaric acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-toluenesulfonic acid, benzenesulfonic acid, succinic acid, tannic acid and tartaric acid. 
Farmaceutski sastav prema zahtjevu 16, naznačen time, da su navedene fiziološki prihvatljive kiseline odabrane iz skupine koju čine: klorovodična kiselina, bromovodična kiselina, sumporna kiselina, fosforna kiselina, dušična kiselina, octena kiselina, askorbinska kiselina, benzojeva kiselina, limunska kiselina, fumarna kiselina, mliječna kiselina, maleična kiselina, metansulfonska kiselina, oksalna kiselina, para-toluensulfonska kiselina, benzensulfonska kiselina, sukcinska kiselina, taninska kiselina i vinska kiselina.
Pharmaceutical composition according to Claim 11, characterized in that the said physiologically acceptable bases are chosen from the group comprising ammonium hydroxide, calcium hydroxide, magnesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, N-methylglucamine, glucamine, glucosamine, histidine, N-(2-hydroxyethyl)piperidine, N-(2-hydroxyethyl)pyrrolidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, theobromine, triethylamine, trimethylamine, tripropylamine and tromethamine. 
Farmaceutski sastav prema zahtjevu 11, naznačen time, da su navedene fiziološki prihvatljive lužine odabrane iz skupine koju čine: amonijev kidroksid, kalcijev hidroksid, magnezijev karbonat, natrij-vodikov karbonat, kalij-vodikov karbonat, arginin, betain, kafein, kolin, N,N-dibenziletilendiamin, dietilamin, 2-dietilaminoetanol, 2-dimetilaminoetanol, etanolamin, etilendiamin, N-etilmorfolin, N-etilpiperidin, N-metilglukamin, glukamin, glukozamin, histidin, N-(2-hidroksietil)piperidin, N-(2-hidroksietil)pirolidin, izopropilamin, lizin, metilglukamin, morfolin, piperazin, piperidin, teobromin, trietilamin, trimetilamin, tripropilamin i trometamin.
Pharmaceutical composition according to any one of Claims 15 to 19, characterized in that the said composition contains a stereoisomer or an enantiomer of the compound of formula (I), or a pharmaceutically acceptable salt, or ester thereof, or a mixture thereof. 
Farmaceutski sastav prema bilo kojem od zahtjeva 15 do 19, naznačen time, da navedeni sastav sadrži stereoizomer ili enantiomer od spoja formule (I), ili njegovu farmaceutski prihvatljivu sol, ili njegov ester, ili mješavinu od navedenoga.
may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, COR', COOR', CON(R')(R") with R' and R", which may be identical or different each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms, or R12 together with R11, forms a 4- to 7-membered heterocycle, 
može biti vodik, alkil-skupina koja ima od 1 do 5 atoma ugljika, alkoksi- skupina koja ima od 1 do 3 atoma ugljika, COR', COOR', CON(R')(R"), s R' i R” koji mogu biti međusobno isti ili različiti, a predstavljeni su vodikom ili alkil-skupinom koja ima od 1 do 5 atoma ugljika, ili R12 zajedno s R11 tvori 4-člani do 7-člani heterocikl,
R3, R4 and R8, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", -CN, -CONR'R", -SO2NR'R", -SO2R', nitro and trifluoromethyl; with R' and R", which may be identical or different each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms, 
, R4 i R8 koji mogu biti međusobno isti ili različiti, mogu biti vodik, alkil-skupina koja ima od 1 do 5 atoma ugljika, alkoksi-skupina koja ima od 1 do 3 atoma ugljika, atom halogena, -OH, -N(R')(R"), -N(R’)COR", -CN, -CONR'R", -SO2NR'R", -SO2R' nitro i trifluorometil, s R' i R" koji mogu biti međusobno isti ili različiti, a predstavljeni su vodikom i alkil-skupinom koja ima od 1 do 5 atoma ugljika,
may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, - N(R')(R"), -N(R')COR", nitro and trifluoromethyl, or R5 together with one from between R6 and R7 forms a ring having 5 or 6 carbon atoms; with R' and R", which may be identical or different each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms, and R7, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, or together form a group C=O, or one from between R6 and R7, together with R5, forms a ring having 5 or 6 carbon atoms, 
može biti vodik, alkil-skupina koja ima od 1 do 5 atoma ugljika, alkoksi- skupina od 1 do 3 atoma ugljika, atom halogena, -OH, -N(R')(R"), -N(R')COR", nitro i trifluorometil, ili zajedno s jednim između R6 i R7, tvori prsten koji ima 5 ili 6 atoma ugljika, s R' i R" koji mogu biti međusobno isti ili različiti, a predstavljeni su vodikom i alkil-skupinom koja ima od 1 do 5 atoma ugljika, i R7 koji mogu biti međusobno isti ili različiti, mogu biti vodik, alkil-skupina koja ima od 1 do 5 atoma ugljika, ili zajedno tvore skupinu C=0, ili jedan između R6 i R7, zajedno s R5, tvori prsten koji ima 5 ili 6 atoma ugljika, naznačena time, daje za proizvodnju farmaceutskog pripravka za liječenje bolesti koje se baziraju na ekspresiji MCP-1 i CX3CR1, i koje su odabrane iz sljedeće skupine: artikularne bolesti, renalne bolesti, kardiovaskularne bolesti, metabolički sindrom, pretilost, dijabetes, otpornost na inzulin i rak.
Use according to Claim 17, characterized in that the said diseases based on the expression of MCP-1 are chosen from the group comprising rheumatoid arthritis, arthritis induced by viral infections, psoriatic arthritis, arthrosis, lupus nephritis, diabetic nephropathy, glomerulonephritis, polycystic kidney disease, interstitial lung disease, fibrosis, multiple sclerosis, Alzheimer's disease, HIV-associated dementia, atopic dermatitis, psoriasis, vasculitis, restenosis, atherosclerosis, myocardial infarction, angina, acute coronary diseases, adenomas, carcinomas and metastases, and metabolic diseases. 
Uporaba prema zahtjevu 17, naznačena time, da su spomenute bolesti koje se baziraju na ekspresiji MCP-1, odabrane iz skupine koju čine: reumatoidni artritis, artritis induciran virusnom infekcijom, psorijatični artritis, artroza, lupus nefritis, dijabetska nefropatija, glomerulonefritis, bolest policističnih bubrega, intersticijska bolest pluća, fibroza, multipla skleroza, Alzheimerova bolest, demencija povezana s HlV-om, atopični dermatitis, psorijaza, vaskulitis, restenoza, ateroskleroza, infarkt miokarda, angina, akutna koronarna bolest, adenomi, karcinomi i metastaze, te metaboličke bolesti.
Use according to Claim 17, characterized in that the said diseases based on the expression of CX3CR1 are chosen from the group comprising rheumatoid arthritis, lupus nephritis, diabetic nephropathy, Crohn's disease, ulcerative colitis, coronary disorders, restenosis, atherosclerosis, myocardial infarction, and angina. 
Uporaba prema zahtjevu 17, naznačena time, da su spomenute bolesti koje se baziraju na ekspresiji CX3CR1, odabrane iz skupine koju čine: reumatoidni artritis, lupus nefritis, dijabetska nefropatija, Chronova bolest, ulcerativni kolitis, koronarni poremećaji, restenoza, ateroskleroza, infarkt miokarda i angina.
A method of preparing tiotropium bromide of formula II characterized in that it comprises the following steps: 
Postupak priprave tiotropij bromida formule II [image] naznačen time, da se sastoji od sljedećih koraka:
The method according to claim 1, characterized in that the sterically hindered base is selected from the group of the sodium or potassium salts of tert- butoxide, tert -pentoxide, and isopropoxide. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je sterički ometana lužina odabrana iz skupine natrijevih ili kalijevih soli terc-butoksida, terc-pentoksida i izopropoksida.
The method according to claim 1, characterized in that toluene, tetrahydrofuran or their mixtures are used as the inert solvent. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da su toluen, tetrahidrofuran ili njihove smjese korištene kao intertno otapalo.
The method according to claim 8, characterized in that dichloromethane is used as the extraction agent. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time, da je diklorometan korišten kao sredstvo za ekstrakciju.
The method according to claim 8, characterized in that the crystallizing solvent is acetonitrile or toluene or their mixtures. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time, da je kristalizacijsko otapalo acetonitril ili toluen ili smjesa istih.
an effective amount of a narcotic active ingredient selected from the group consisting of Fentanyl and pharmaceutically acceptable salts thereof, and ii) a pharmaceutically acceptable amine having a pK of 8 or greater, wherein said amine is Arginine, wherein the molar ratio of amine:active ingredient is at least 5:1. 
učinkovitu količinu narkotika kao djelatne tvari, izabranog iz skupine koju čine fentanil i njegove farmaceutski prikladne soli, i ii) farmaceutski prikladan amin čiji je pK 8 ili veći, gdje je taj amin arginin, gdje je molarni omjer amin:djelatna tvar najmanje 5:1.
Use of a chimeric peptide according to claim 13 for the preparation of a pharmaceutical composition for treating stroke, brain trauma, spiral cord injury, amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease and Parkinson's disease. 
Uporaba kimernog peptida prema zahtjevu 9 naznačena time da je za pripremanje farmaceutskog pripravka za liječenje kapi, moždane traume, ozljede leđne moždine, amiotrofične lateralne skleroze, Huntingtonove bolesti, Alzheimerove bolesti i Parkinsonove bolesti.
The combination of claim 1 wherein the cancer is selected from the group consisting of breast cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, colorectal carcinoma, prostate cancer, renal cell carcinoma, melanoma, hepatocellular carcinoma, cervical cancer, sarcoma, brain tumor, gastric cancer, multiple myeloma, leukemia, and lymphoma. 
Sastav za uporabu u skladu s patentnim zahtjevom 1, pri čemu je karcinom odabran iz grupe koja se sastoji od karcinoma dojke, karcinoma glave i vrata, karcinoma pluća, karcinoma jajnika, karcinoma gušterače, kolorektalnog karcinoma, karcinoma prostate, melanoma, sarkoma, karcinoma jetre, tumora na mozgu, multiplog mijeloma i leukemije.
identifying or determining the carbohydrates and/or the carbohydrate mixture composition patterns wherein the standard composition is added to the sample containing the unknown carbohydrate mixture composition, and wherein the standard of known composition is a known carbohydrate mixture composition. 
identifikacije ili određivanje ugljikohidrata i/ili uzoraka sastava ugljikohidratne smjese. pri čemu se standardni sastav dodaje uzorku koji sadrži nepoznati sastav smjese ugljikohidrata i pri čemu je standard poznatog sastava standardna skala parova baza.
comparing the standard migration time indices calculated from the obtained electropherogram of the first sample and the second sample; 
usporedbe indeksa standardnih vremena migracije izračunatih iz dobivenog elektroferograma prvog uzorka i drugog uzorka;
wherein standard migration time indices of the carbohydrates present in the samples are calculated based on internal standards of known composition whereby the internal standard is added to the samples to be analysed, and wherein the standard is a known carbohydrate mixture composition. 
pri čemu se indeksi standardnog vremena migracije ugljikohidrata prisutnog u uzorku izračunavaju na temelju unutarnjih standarda poznatog sastava, pri čemu je standard poznatog sastava standardna skala parova baza i pri čemu se standard dodaje uzorcima koje treba analizirati.